Jazz Pharmaceuticals Plans $1 Bln Notes Offering, Concurrent $225 Mln Share Buyback
(RTTNews) - Jazz Pharmaceuticals plc (JAZZ), a biopharmaceutical company, on Wednesday announced plans to offer $1 billion of exchangeable senior notes due 2032 in a private offering.
Jazz Pharmaceuticals plc announced the pricing of $1.1 billion in exchangeable senior notes due in 2032, a size increase from the initial $1.0 billion offering. The notes, issued by Jazz Investments I Limited, grant initial purchasers the option to buy an additional $150 million within 13 days. Set to mature on September 15, 2032, the notes offer a semiannual interest rate of 1.875% starting March 15, 2027.
The exchange rate is 2.8150 ordinary shares per $1,000 principal amount, with an initial price around $355.24 per share, marking a 42.5% premium compared to the previous Nasdaq sale. The issuer may redeem the notes on or after September 20, 2029, if the share price hits 130% of the exchange price for 20 consecutive trading days.
Jazz estimates net proceeds of approximately $1.079 billion post-expenses, or $1.226 billion if all initial purchasers exercise their option. The funds will be used for general corporate purposes, including the repurchase of around $225 million of ordinary shares from note holders at $249.29 each, as part of the company's share repurchase program initiated in July 2024.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
